Compare Recursion Pharmaceuticals Inc (RXRX) vs Block Inc (XYZ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs Block Inc — how do they compare? Recursion Pharmaceuticals Inc trades at $4.36 (market cap $2.14B), while Block Inc trades at $77.24 (market cap $45.20B). The key difference: Block Inc is far larger — about 21.1× Recursion Pharmaceuticals Inc's market cap, and Block Inc is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Recursion Pharmaceuticals Inc for 23 Days and Block Inc for 78 Days on average.
| RXRX | XYZ | |
|---|---|---|
Market Cap | $2.14B | $45.20B |
Volume | 30,789,535 | 8,386,094 |
Sector | Health | Technology |
52-Week High | $6.79 | $84.85 |
52-Week Low | $2.84 | $49.04 |
Typical Hold Time | 23 Days | 78 Days |
Enterprise Value | $1.66B | $40.10B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RXRX trades at $3.95, down 7.49% in the last session, reflecting ongoing volatility. The company reported a net loss of $644.76M in 2025, with a negative net income margin of -961.97%, though recent quarters have shown mixed earnings beats. Technical indicators are bullish overall, with moving averages signaling strength. Strategic partnerships, such as the extended data license with Tempus AI (Business Wire, 2026-09-21), aim to bolster its AI-driven drug discovery platform, but high cash burn remains a concern.
The outlook is cautious; while analyst consensus is 40% buy and 60% hold (MarketBeat, 2026-09-20), the stock faces significant risks from persistent losses and slow revenue growth. Upside potential hinges on pipeline success, but investors must weigh the high valuation (P/S of 37.14) against operational challenges and competitive pressures in biotech.
XYZ trades at $75.21, down 1.13% on the day, with a bearish technical signal but strong analyst support. The company reported mixed earnings, beating in Q1 and Q2 2026 but missing in Q4 2025, with Q3 results pending. Revenue growth has been steady, reaching $24.19B in 2025, though net income margin compressed to 1.43%. Cash flow trends show volatility, with 2025 net cash flow negative $749.24M due to heavy investing activity.
The stock offers potential upside to the consensus price target of $97.47, supported by a 76.9% buy rating from analysts. However, risks include high P/E of 134.34, margin pressures, and insider selling. Positive developments include expanding partnerships and a potential federal trust bank application, which could enhance profitability long-term.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About Block Inc
Founded in 2009, Block provides payment acquiring services to merchants, along with related services. The company also launched Cash App, a person-to-person payment network. Block has operations in Canada, Japan, Australia, and the United Kingdom
Read more on XYZ →
